The Antibody Society presents:



Antibody Validation Webinar Series

WEBINAR 10: Specific Detection Reagents: What's the Future?

Moderator: Dr. Simon Goodman, The Antibody Society

Speaker: Prof. Andreas Plückthun, University of Zürich

First Broadcast: February 19, 2020

Now available On Demand

Questions and Answers from the live Webcast on February 19, 2020

Question	Answer
DARPins are small molecules. What about the clearance and half-life of DARPins in clinical studies compared to antibodies?	This is true. However, it is very easy to provide them with long half-life, e.g. by fusing them to an albumin-binding domain (as in the clinic) or PEG. This is a standard procedure by now.
How do I decide on the number of repeats for a DARPin scaffold when I want to perform a directed evolution against a new antigen?	As a standard, we use libraries with three randomized repeats, or two, flanked by capping repeats. That has about the same contact surface as a Fab.
Thanks to the speakers and organizers for an informative series.	**SG:** We are very happy that you found the series useful. Please spread the word if you found it an aid.

All episodes in this 10-part webinar series are now available On Demand.

Please visit our Learning Center to access the registration links.